Access the full text.
Sign up today, get DeepDyve free for 14 days.
Amit Deshpande, P. Sicinski, P. Hinds (2005)
Cyclins and cdks in development and cancer: a perspectiveOncogene, 24
R. Elaidi, Y. Vano, N. Aide, L. Fournier, D. Deandreis, F. Tenenbaum, R. Lebtahi, H. Clermont-Galleran, L. Albiges, B. Escudier, F. Joly, J. Alexandre, M. Bernardini, S. Baron, J. Arfi-Rouche, C. Noel, E. Braychenko, J. O'Quigley, J. Medioni, S. Oudard (2016)
Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastasesAnnals of Oncology, 27
M. Herrera-Abreu, M. Palafox, U. Asghar, Martín Rivas, R. Cutts, I. Garcia-Murillas, A. Pearson, M. Guzman, Olga Rodríguez, J. Grueso, M. Bellet, J. Cortés, R. Elliott, S. Pancholi, J. Baselga, M. Dowsett, L. Martin, N. Turner, V. Serra (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.Cancer research, 76 8
R. Finn, J. Crown, I. Láng, K. Boér, I. Bondarenko, Sergey Kulyk, J. Ettl, Ravi Patel, T. Pintér, Marcus Schmidt, Y. Shparyk, A. Thummala, N. Voytko, C. Fowst, Xin Huang, Sindy Kim, S. Randolph, D. Slamon (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.The Lancet. Oncology, 16 1
D. Donjerković, David Scott (2000)
Regulation of the G1 phase of the mammalian cell cycleCell Research, 10
A. Walker, S. Wedam, L. Amiri-Kordestani, E. Bloomquist, Sheng-liang Tang, R. Sridhara, Wei Chen, Todd Palmby, Jeanne Zirkelbach, W. Fu, Qi Liu, A. Tilley, Geoffrey Kim, P. Kluetz, Amy McKee, R. Pazdur (2016)
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast CancerClinical Cancer Research, 22
P. Sicinski, R. Weinberg (1997)
A Specific Role for Cyclin D1 in Mammary Gland DevelopmentJournal of Mammary Gland Biology and Neoplasia, 2
Marcos Malumbres, M. Barbacid (2001)
Milestones in cell division: To cycle or not to cycle: a critical decision in cancerNature Reviews Cancer, 1
T. Wang, R. Cardiff, L. Zukerberg, E. Lees, A. Arnold, E. Schmidt (1994)
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic miceNature, 369
J. Baselga, M. Campone, M. Piccart, H. Burris, H. Rugo, T. Sahmoud, S. Noguchi, M. Gnant, K. Pritchard, F. Lebrun, J. Beck, Yoshinori Ito, D. Yardley, I. Deleu, Alejandra Perez, T. Bachelot, L. Vittori, Zhi-Xia Xu, P. Mukhopadhyay, D. Lebwohl, G. Hortobagyi (2012)
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.The New England journal of medicine, 366 6
R. Zwijsen, E. Wientjens, R. Klompmaker, Jeroen Sman, R. Bernards, R. Michalides (1997)
CDK-Independent Activation of Estrogen Receptor by Cyclin D1Cell, 88
Jong Kim, J. Diehl (2009)
Nuclear cyclin D1: An oncogenic driver in human cancerJournal of Cellular Physiology, 220
L. Gelbert, S. Cai, Xi Lin, Concha Sánchez-Martínez, M. Prado, M. Lallena, R. Torres, R. Ajamie, Graham Wishart, R. Flack, B. Neubauer, Jamie Young, E. Chan, P. Iversen, D. Cronier, E. Kreklau, A. Dios (2014)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabineInvestigational New Drugs, 32
S. Goel, Qi Wang, April Watt, S. Tolaney, D. Dillon, Wei Li, S. Ramm, S. Ramm, A. Palmer, A. Palmer, Haluk Yuzugullu, V. Varadan, D. Tuck, L. Harris, Kwok-kin Wong, X. Liu, P. Sicinski, E. Winer, I. Krop, Jean Zhao, Jean Zhao (2016)
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.Cancer cell, 29 3
R. Finn, Yuqiu Jiang, H. Rugo, S. Moulder, S. Im, K. Gelmon, V. Diéras, M. Martín, A. Joy, M. Toi, E. Gauthier, D. Lu, C. Bartlett, D. Slamon (2016)
Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)Annals of Oncology, 27
A. DeMichele, A. Clark, K. Tan, D. Heitjan, Kristi Gramlich, M. Gallagher, P. Lal, M. Feldman, Paul Zhang, Christopher Colameco, D. Lewis, Melissa Langer, N. Goodman, S. Domchek, K. Gogineni, M. Rosen, K. Fox, P. O'dwyer (2014)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker AssessmentClinical Cancer Research, 21
C. Sherr, James Roberts (2004)
Living with or without cyclins and cyclin-dependent kinases.Genes & development, 18 22
J. Beaver, L. Amiri-Kordestani, R. Charlab, Wei Chen, Todd Palmby, A. Tilley, J. Zirkelbach, Jingyu Yu, Qi Liu, Liang Zhao, J. Crich, X. Chen, Minerva Hughes, E. Bloomquist, Shenghui Tang, R. Sridhara, P. Kluetz, Geoffrey Kim, A. Ibrahim, R. Pazdur, P. Cortazar (2015)
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast CancerClinical Cancer Research, 21
J. Franco, U. Balaji, Elizaveta Freinkman, A. Witkiewicz, E. Knudsen (2016)
Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.Cell reports, 14 5
R. Finn, A. Aleshin, D. Slamon (2016)
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancersBreast Cancer Research : BCR, 18
B. Lehmann, Joshua Bauer, X. Chen, M. Sanders, A. Chakravarthy, Y. Shyr, J. Pietenpol (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.The Journal of clinical investigation, 121 7
M Malumbres, M Barbacid (2001)
To cycle or not to cycle: a critical decision in cancerNat Rev Cancer, 1
Joshua McMichael, L. Fulton, D. Dooling, Li Ding, R. Elaine, Mardis, R. Wilson, Miruna, Balasundaram, R. Carlsen, Candace Carter, Andy, M Chu, E. Chuah, Noreen Dhalla, Ranabir, Guin, Carrie Hirst, M. Hirst, R. Holt, D. Lee, Michael, Mayo, Richard Moore, A. Mungall, E. Pleasance, A. GordonRobertson, J. Schein, A. Shafiei, Payal Sipahimalani, Jared Slobodan, Yongjun Zhao, I. Birol, Steven Jones, R. Onofrio, S. Carter, S. Schumacher, B. Tabak, Bryan Hernandez, R. Beroukhim, W. Winckler, S. Gabriel, A. Prat, Grace Silva, Jerry Usary, Douglas Voet, N. Gehlenborg, Mike Lawrence, Lihua, Zou, Pei Lin, R. Jing, JuokCho, Raktim, Sinha, R. Park, Marc-Danie Nazaire, James Robinson, Helga, Thorvaldsdottir, J. Mesirov, Peter Park, L. Chin, R. Kreisberg, A. Jacobsen, Rileen Sinha, B. Reva, R. Shen, B. Taylor, Tod Casasent, A. Unruh, Joshua Stuart, Jingchun Zhu, Chris Szeto, G. Scott, C. Yau, Evan, O. Paull, Daniel Carlin, Artem Sokolov, J. Thusberg, S. Mooney, Jay Bowen, N. Ramirez, D. Aaron, Black, R. Pyatt, P. White, E. Zmuda, J. Frick, M. Tara, Lichtenberg, Robin Brookens, Myra George, Mark Gerken, A. Hollie, Harper, K. Leraas, Teresa Tabler (2013)
Comprehensive molecular portraits of human breast tumoursYearbook of Pathology and Laboratory Medicine, 2013
Peilu Wang, A. Bahreini, R. Gyanchandani, P. Lucas, R. Hartmaier, R. Watters, Amruth Jonnalagadda, H. Bittar, A. Berg, R. Hamilton, B. Kurland, K. Weiss, A. Mathew, J. Leone, N. Davidson, M. Nikiforova, A. Brufsky, T. Ambros, A. Stern, S. Puhalla, Adrian Lee, S. Oesterreich (2015)
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer PatientsClinical Cancer Research, 22
R. Finn, J. Dering, D. Conklin, O. Kalous, David Cohen, Amrita Desai, C. Ginther, M. Atefi, I. Chen, C. Fowst, G. Los, D. Slamon (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research : BCR, 11
J. Baselga, S. Im, H. Iwata, M. Clemons, Yoshinori Ito, A. Awada, S. Chia, A. Jagiełło-Gruszfeld, B. Pistilli, L. Tseng, S. Hurvitz, N. Masuda, J. Cortes, M. Laurentiis, C. Arteaga, Zefei Jiang, W. Jonat, S. Hachemi, S. Mouhaër, E. Tomaso, P. Urban, C. Massacesi, M. Campone (2016)
Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial:Cancer Research, 76
Y. Choi, Xiao-yu Li, P. Hydbring, Takaomi Sanda, Takaomi Sanda, Joanna Stefano, A. Christie, Sabina Signoretti, Sabina Signoretti, A. Look, A. Look, Andrew Kung, Harald Boehmer, P. Sicinski (2012)
The requirement for cyclin D function in tumor maintenance.Cancer cell, 22 4
Qunyan Yu, E. Sicinska, Y. Geng, Marie Ahnström, A. Zagozdzon, Y. Kong, H. Gardner, H. Kiyokawa, L. Harris, O. Stål, P. Sicinski (2006)
Requirement for CDK4 kinase function in breast cancer.Cancer cell, 9 1
M. Dickler, S. Tolaney, H. Rugo, J. Cortés, V. Diéras, D. Patt, H. Wildiers, Martin Frenzel, A. Koustenis, J. Baselga (2016)
MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.Journal of Clinical Oncology, 34
(2016)
PALOMA-2: primary results from a phase 3 trial of palbociclib plus letrozole compared with placebo plus letrozole in postmenopausal women with ER+/HER2− advanced breast cancer
Jeffry Dean, A. McClendon, Theresa Hickey, L. Butler, W. Tilley, A. Witkiewicz, E. Knudsen (2012)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumorsCell Cycle, 11
C. Yang, Zhiqiang Li, Tanvi Bhatt, M. Dickler, D. Giri, Scaltriti Maurizio, Scaltriti Maurizio, J. Baselga, J. Baselga, Neal Rosen, Neal Rosen, S. Chandarlapaty, S. Chandarlapaty (2016)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependenceOncogene, 36
M. Cristofanilli, N. Turner, I. Bondarenko, J. Ro, S. Im, N. Masuda, M. Colleoni, A. DeMichele, S. Loi, S. Verma, H. Iwata, N. Harbeck, Ke Zhang, K. Theall, Yuqiu Jiang, C. Bartlett, M. Koehler, D. Slamon (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.The Lancet. Oncology, 17 4
M. Dickler, C. Saura, D. Richards, I. Krop, A. Cervantes, P. Bedard, M. Patel, L. Pusztai, Mafalda Oliveira, J. Ware, Huan Jin, T. Wilson, Tj Stout, M. Wei, J. Hsu, J. Baselga (2016)
A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).Journal of Clinical Oncology, 34
C. Saura, J. Sachdev, M. Patel, A. Cervantes, D. Juric, J. Infante, D. Richards, S. Sanabria, Xuyang Lu, J. Ware, T. Wilson, H. Parmar, J. Hsu, Mafalda Oliveira, E. Winer, D. Hoff, J. Baselga, I. Krop (2015)
Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancerCancer Research, 75
R. Beroukhim, C. Mermel, D. Porter, G. Wei, S. Raychaudhuri, Jerry Donovan, J. Barretina, J. Boehm, Jennifer Dobson, M. Urashima, Kevin Henry, Reid Pinchback, A. Ligon, Yoon-Jae Cho, Leila Haery, H. Greulich, Michael Reich, W. Winckler, M. Lawrence, B. Weir, K. Tanaka, Derek Chiang, A. Bass, Alice Loo, Carter Hoffman, John Prensner, T. Liefeld, Qing Gao, Derek Yecies, S. Signoretti, E. Maher, F. Kaye, H. Sasaki, J. Tepper, J. Fletcher, J. Tabernero, J. Baselga, M. Tsao, F. Demichelis, M. Rubin, P. Janne, M. Daly, C. Nucera, R. Levine, B. Ebert, S. Gabriel, A. Rustgi, C. Antonescu, M. Ladanyi, A. Letai, L. Garraway, M. Loda, D. Beer, L. True, A. Okamoto, S. Pomeroy, S. Singer, T. Golub, E. Lander, G. Getz, W. Sellers, M. Meyerson (2010)
The landscape of somatic copy-number alteration across human cancersNature, 463
A. Patnaik, L. Rosen, S. Tolaney, A. Tolcher, J. Goldman, L. Gandhi, K. Papadopoulos, M. Beeram, D. Rasco, J. Hilton, A. Nasir, R. Beckmann, A. Schade, Angie Fulford, Tuan Nguyen, R. Martinez, P. Kulanthaivel, Lily Li, Martin Frenzel, D. Cronier, E. Chan, K. Flaherty, P. Wen, G. Shapiro (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.Cancer discovery, 6 7
M. Blagosklonny, A. Pardee (2002)
The Restriction Point of the Cell CycleCell Cycle, 1
J. Weber, D. Raben, Polly Phillips, J. Baldassare (1997)
Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase.The Biochemical journal, 326 ( Pt 1)
Jeffry Dean, C. Thangavel, A. Mcclendon, C. Reed, E. Knudsen (2010)
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failureOncogene, 29
J. Thigpen (2012)
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerYearbook of Oncology, 2012
J. Parker, Michael Mullins, M. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, Xiaping He, Zhiyuan Hu, J. Quackenbush, I. Stijleman, J. Palazzo, J. Marron, A. Nobel, E. Mardis, T. Nielsen, M. Ellis, C. Perou, P. Bernard (2009)
Supervised risk predictor of breast cancer based on intrinsic subtypes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 8
Qunyan Yu, Y. Geng, P. Sicinski (2001)
Specific protection against breast cancers by cyclin D1 ablationNature, 411
J. Baselga, S. Im, H. Iwata, M. Clemons, Yoshinori Ito, A. Awada, S. Chia, Agnieszka Jagie, o-Gruszfeld, B. Pistilli, L. Tseng, S. Hurvitz, N. Masuda, J. Cortés, M. Laurentiis, C. Arteaga, Zefei Jiang, W. Jonat, S. Hachemi, S. Mouhaër, E. Tomaso, P. Urban, C. Massacesi, M. Campone (2015)
PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib Plus Fulvestrant in Postmenopausal Women With Endocrine-resistant HR+/HER2- Advanced Breast Cancer: First Results From the Randomized, Phase III BELLE-2 Trial
R. Jeselsohn, R. Yelensky, Gilles Buchwalter, G. Frampton, F. Meric-Bernstam, A. González-Angulo, J. Ferrer-Lozano, J. Pérez-Fidalgo, M. Cristofanilli, H. Gómez, C. Arteaga, J. Giltnane, J. Balko, M. Cronin, M. Jarosz, James Sun, Matthew Hawryluk, D. Lipson, G. Otto, J. Ross, A. Dvir, L. Soussan-Gutman, I. Wolf, T. Rubinek, Lauren Gilmore, S. Schnitt, S. Come, L. Pusztai, P. Stephens, Myles Brown, V. Miller (2014)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast CancerClinical Cancer Research, 20
C. Fribbens, B. O’Leary, L. Kilburn, S. Hrebien, I. Garcia-Murillas, M. Beaney, M. Cristofanilli, F. André, S. Loi, S. Loibl, John Jiang, C. Bartlett, M. Koehler, M. Dowsett, J. Bliss, S. Johnston, N. Turner (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 25
Phase Ib study of the PI 3 K inhibitor taselisib ( GDC - 0032 ) in combination with letrozole in patients with hormone receptor - positive advanced breast cancer
(1996)
Regulation of the cell cycle machinery by oncogenic
L. Anders, N. Ke, P. Hydbring, Y. Choi, H. Widlund, Joel Chick, Huili Zhai, M. Vidal, S. Gygi, P. Braun, P. Sicinski (2011)
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.Cancer cell, 20 5
M. Cheng, V. Sexl, C. Sherr, M. Roussel (1998)
Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1).Proceedings of the National Academy of Sciences of the United States of America, 95 3
D. Koboldt, R. Fulton, M. McLellan, Heather Schmidt, Joelle Kalicki-Veizer, Joshua McMichael, L. Fulton, D. Dooling, L. Ding, E. Mardis, R. Wilson, Adrian Ally, M. Balasundaram, Y. Butterfield, R. Carlsen, Candace Carter, Andy Chu, E. Chuah, Hye-Jung Chun, R. Coope, Noreen Dhalla, R. Guin, Carrie Hirst, M. Hirst, R. Holt, Darlene Lee, H. Li, Michael Mayo, Richard Moore, A. Mungall, E. Pleasance, A. Robertson, J. Schein, A. Shafiei, Payal Sipahimalani, Jared Slobodan, D. Stoll, Angela Tam, N. Thiessen, R. Varhol, N. Wye, Thomas Zeng, Yongjun Zhao, I. Birol, Steven Jones, M. Marra, A. Cherniack, G. Saksena, R. Onofrio, Nam Pho, S. Carter, S. Schumacher, B. Tabak, Bryan Hernandez, Jeff Gentry, Huy Nguyen, A. Crenshaw, K. Ardlie, R. Beroukhim, W. Winckler, G. Getz, S. Gabriel, M. Meyerson, L. Chin, R. Kucherlapati, K. Hoadley, J. Auman, C. Fan, Yidi Turman, Yan Shi, Ling Li, M. Topal, Xiaping He, H. Chao, A. Prat, Grace Silva, M. Iglesia, Wei Zhao, Jerry Usary, J. Berg, Michael Adams, J. Booker, Junyuan Wu, Anisha Gulabani, T. Bodenheimer, A. Hoyle, J. Simons, Matthew Soloway, Lisle Mose, S. Jefferys, S. Balu, J. Parker, D. Hayes, C. Perou, Simeen Malik, S. Mahurkar, Hui Shen, D. Weisenberger, T. Triche, Phillip Lai, M. Bootwalla, D. Maglinte, B. Berman, D. Berg, S. Baylin, P. Laird, C. Creighton, L. Donehower, M. Noble, Douglas Voet, N. Gehlenborg, D. Cara, Juinhua Zhang, Hailei Zhang, Chang-Jiun Wu, Spring Liu, M. Lawrence, L. Zou, A. Sivachenko, Pei Lin, P. Stojanov, R. Jing, Juok Cho, Raktim Sinha, R. Park, Marc-Danie Nazaire, James Robinson, H. Thorvaldsdóttir, J. Mesirov, P. Park, Sheila Reynolds, R. Kreisberg, Brady Bernard, Ryan Bressler, Timo Erkkilä, Jake Lin, V. Thorsson, Wei Zhang, I. Shmulevich, G. Ciriello, Nils Weinhold, N. Schultz, Jianjiong Gao, E. Cerami, Benjamin Gross, A. Jacobsen, Rileen Sinha, B. Aksoy, Yevgeniy Antipin, B. Reva, R. Shen, B. Taylor, M. Ladanyi, C. Sander, Pavana Anur, P. Spellman, Yiling Lu, Wenbin Liu, R. Verhaak, G. Mills, R. Akbani, Nianxiang Zhang, B. Broom, Tod Casasent, Chris Wakefield, A. Unruh, K. Baggerly, K. Coombes, J. Weinstein, D. Haussler, C. Benz, Joshua Stuart, S. Benz, Jingchun Zhu, C. Szeto, G. Scott, C. Yau, Evan Paull, Daniel Carlin, Christopher Wong, Artem Sokolov, J. Thusberg, S. Mooney, S. Ng, Theodore Goldstein, K. Ellrott, Mia Grifford, C. Wilks, Singer Ma, Brian Craft, Chunhua Yan, Ying Hu, D. Meerzaman, J. Gastier-Foster, Jay Bowen, N. Ramirez, Aaron Black, R. Pyatt, P. White, E. Zmuda, J. Frick, T. Lichtenberg, Robin Brookens, Myra George, M. Gerken, H. Harper, K. Leraas, L. Wise, Teresa Tabler, Cynthia McAllister, T. Barr, Melissa Hart-Kothari, Katherine Tarvin, Charles Saller, G. Sandusky, Colleen Mitchell, M. Iacocca, Jennifer Brown, B. Rabeno, Christine Czerwinski, N. Petrelli, Oleg Dolzhansky, M. Abramov, Olga Voronina, O. Potapova, J. Marks, W. Suchorska, D. Murawa, W. Kycler, Matthew Ibbs, Konstanty Korski, A. Spychała, P. Murawa, Jacek Brzeziński, Hanna Perz, Radoslaw Łaźniak, M. Teresiak, Honorata Tatka, E. Leporowska, M. Bogusz-Czerniewicz, J. Malicki, A. Mackiewicz, M. Wiznerowicz, X. Le, B. Kohl, N. Tien, Richard Thorp, N. Bang, H. Sussman, Bui Phu, R. Hajek, N. Hung, H. Thang, K. Khan, R. Penny, D. Mallery, Erin Curley, C. Shelton, P. Yena, J. Ingle, F. Couch, W. Lingle, T. King, A. González-Angulo, Mary Dyer, Shuying Liu, Xiaolong Meng, Modesto Patangan, F. Waldman, H. Stoppler, W. Rathmell, L. Thorne, Meijuan Huang, L. Boice, Ashley Hill, C. Morrison, Carmelo Gaudioso, W. Bshara, K. Daily, Sophie Egea, M. Pegram, C. Gomez-Fernandez, R. Dhir, R. Bhargava, A. Brufsky, C. Shriver, J. Hooke, J. Campbell, R. Mural, Hai Hu, S. Somiari, C. Larson, B. Deyarmin, L. Kvecher, A. Kovatich, M. Ellis, T. Stricker, K. White, O. Olopade, C. Luo, Y. Chen, R. Bose, Li-Wei Chang, Andrew Beck, T. Pihl, M. Jensen, R. Sfeir, A. Kahn, A. Chu, Prachi Kothiyal, Zhining Wang, E. Snyder, J. Pontius, Brenda Ayala, M. Backus, Jessica Walton, J. Baboud, D. Berton, M. Nicholls, Deepak Srinivasan, R. Raman, Stanley Girshik, Peter Kigonya, S. Alonso, Rashmi Sanbhadti, S. Barletta, D. Pot, Margi Sheth, John Demchok, K. Shaw, Liming Yang, G. Eley, M. Ferguson, R. Tarnuzzer, J. Zhang, Laura Dillon, K. Buetow, P. Fielding, B. Ozenberger, M. Guyer, H. Sofia, Jacqueline Palchik (2012)
Comprehensive molecular portraits of human breast tumorsNature, 490
L. Malorni, Silvano Piazza, Yari Ciani, C. Guarducci, M. Bonechi, C. Biagioni, C. Hart, R. Verardo, A. Leo, I. Migliaccio (2016)
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancerOncotarget, 7
J. Infante, P. Cassier, J. Gerecitano, P. Witteveen, R. Chugh, V. Ribrag, A. Chakraborty, A. Matano, J. Dobson, A. Crystal, S. Parasuraman, G. Shapiro (2016)
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and LymphomasClinical Cancer Research, 22
Eric Klein, R. Assoian (2008)
Transcriptional regulation of the cyclin D1 gene at a glanceJournal of Cell Science, 121
J. Diehl, M. Cheng, M. Roussel, C. Sherr (1998)
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.Genes & development, 12 22
C. Sherr, D. Beach, G. Shapiro (2016)
Targeting CDK4 and CDK6: From Discovery to Therapy.Cancer discovery, 6 4
R. Finn, Miguel Martín, H. Rugo, Stephen Jones, S. Im, K. Gelmon, N. Harbeck, O. Lipatov, J. Walshe, S. Moulder, E. Gauthier, D. Lu, S. Randolph, V. Diéras, D. Slamon (2016)
Palbociclib and Letrozole in Advanced Breast Cancer.The New England journal of medicine, 375 20
N. Turner, C. Bartlett, M. Cristofanilli (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.The New England journal of medicine, 373 17
U. Asghar, M. Herrera-Abreu, R. Cutts, I. Babina, A. Pearson, N. Turner (2015)
Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition.Journal of Clinical Oncology, 33
R. Sutherland, E. Musgrove (2001)
Cyclin D1 and mammary carcinoma: new insights from transgenic mouse modelsBreast Cancer Research, 4
J. Foster, D. Henley, A. Bukovsky, P. Seth, J. Wimalasena (2001)
Multifaceted Regulation of Cell Cycle Progression by Estrogen: Regulation of Cdk Inhibitors and Cdc25A Independent of Cyclin D1-Cdk4 FunctionMolecular and Cellular Biology, 21
M. Cheng, P. Olivier, J. Diehl, M. Fero, M. Roussel, James Roberts, C. Sherr (1999)
The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblastsThe EMBO Journal, 18
G. Schwartz, M. Shah (2005)
Targeting the cell cycle: a new approach to cancer therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 36
Winston Jt, Coats, Wang Yz, Pledger Wj (1996)
Regulation of the cell cycle machinery by oncogenic ras.Oncogene, 12 1
(2016)
MONARCH-1: results from a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2− breast cancer, after chemotherapy for metastatic disease
K. Guan, C. Jenkins, Yan Li, M. Nichols, X. Wu, C. O'keefe, A. Matera, Y. Xiong (1994)
Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.Genes & development, 8 24
(2018)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.The New England journal of medicine, 379 26
B. O’Leary, R. Finn, N. Turner (2016)
Treating cancer with selective CDK4/6 inhibitorsNature Reviews Clinical Oncology, 13
Curr Breast Cancer Rep (2017) 9:26–33 DOI 10.1007/s12609-017-0232-0 TRANSLATIONAL RESEARCH (TA KING AND EA MITTENDORF, SECTION EDITORS) CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure 1 1 Ana C. Garrido-Castro & Shom Goel Published online: 1 February 2017 Springer Science+Business Media New York 2017 Abstract Introduction Purpose of review The purpose of this review is to de- scribe the role of D-type cyclins and cyclin-dependent In order for a healthy cell to divide, it must pass through each kinases (CDKs) 4 and 6 in breast cancer and to discuss stage of the cell cycle in a sequential and tightly orchestrated potential biomarkers for sensitivity or resistance to fashion. The control of cellular proliferation is governed by a CDK4/6 inhibitors. vast array of molecular players, most important of which are the Recent findings A small number of preclinical and clini- cyclins and their partner kinases, the cyclin-dependent kinases cal studies have explored potential mechanisms of (CDKs). Given the fundamental role of dysregulated cellular CDK4/6 inhibitor response and resistance in breast can- proliferation in cancers, it is not surprising, therefore, that the cer. Putative markers of response include estrogen re- development of drugs that inhibit the cyclin/CDK axes
Current Breast Cancer Reports – Springer Journals
Published: Feb 1, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.